MoFo News Item

MoFo Advises Ally Bridge Group in Pulmonx Financing Totaling US$65 Million


Morrison & Foerster represented Ally Bridge Group, a global life-science dedicated investment group, as the lead investor in connection with Pulmonx Corporation’s oversubscribed US$65 million equity financing.

Based in Redwood City, California, Pulmonx is the world leader in interventional pulmonology diagnostics, planning tools, and treatments for obstructive lung disease. The company develops and markets minimally-invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders. The new financing positions Pulmonx to lead the emerging global field of interventional pulmonology.

The MoFo team was led by Hong Kong partner Thomas Chou, co-chair of the firm’s Asia Private Equity Practice and head of the China M&A group, and included San Francisco corporate associates Sara Ayse Uz and Ana Belen Vinueza, and technology transactions associate Dr. Can Cui. Palo Alto patent partner Janet Xiao and San Diego patent associate Bu Yin, as well as Boston finance partner Alexander Rheaume and associate Stephen Queenan, made significant contributions to the deal.

Read the related press release.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.